R21/Matrix-M™ malaria vaccine: A realm of hope for combating malaria in developing countries?
作者信息
Farhan Kanza, Tariq Burhan, Sohail Fiza, Saeed Navera, Akilimali Aymar
机构信息
Jinnah Sindh Medical University, Karachi, Pakistan.
Department of Research, Medical Research Circle (MedReC), Bukavu, Democratic Republic of the Congo.
出版信息
New Microbes New Infect. 2024 Jun 11;60-61:101443. doi: 10.1016/j.nmni.2024.101443. eCollection 2024 Aug-Oct.
Abstract
摘要
相似文献
1
R21/Matrix-M™ malaria vaccine: A realm of hope for combating malaria in developing countries?R21/Matrix-M™疟疾疫苗：发展中国家抗击疟疾的希望之光？
New Microbes New Infect. 2024 Jun 11;60-61:101443. doi: 10.1016/j.nmni.2024.101443. eCollection 2024 Aug-Oct.
2
Safety and immunogenicity of varied doses of R21/Matrix-M™ vaccine at three years follow-up: A phase 1b age de-escalation, dose-escalation trial in adults, children, and infants in Kilifi-Kenya.三年随访中不同剂量的R21/Matrix-M™疫苗的安全性和免疫原性：肯尼亚基利菲针对成人、儿童和婴儿进行的1b期年龄递减、剂量递增试验
Wellcome Open Res. 2023 Oct 12;8:450. doi: 10.12688/wellcomeopenres.19795.1. eCollection 2023.
3
A perspective on Oxford's R21/Matrix-M™ malaria vaccine and the future of global eradication efforts.对牛津大学的 R21/Matrix-M™ 疟疾疫苗的展望及对全球消除疟疾努力的未来的看法。
Malar J. 2024 Jan 12;23(1):16. doi: 10.1186/s12936-024-04846-w.
4
R21/Matrix-M™ malaria vaccine: a new tool to achieve WHO's goal to eliminate malaria in 30 countries by 2030?R21/Matrix-M™ 疟疾疫苗：一种新工具，以实现世卫组织 2030 年在 30 个国家消除疟疾的目标？
J Travel Med. 2023 Dec 28;30(8). doi: 10.1093/jtm/taad140.
5
A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults.在泰国成年人中开展的一项关于疟疾疫苗R21/Matrix-M™联合或不联合抗疟药物的随机试验。
NPJ Vaccines. 2024 Jul 6;9(1):124. doi: 10.1038/s41541-024-00920-1.
6
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.在布基纳法索进行了 2 年的随访后，R21/Matrix-M 疫苗对儿童临床疟疾的疗效和免疫原性：一项 1/2b 期随机对照试验。
Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X. Epub 2022 Sep 7.
7
Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030.社论：两种佐剂疟疾疫苗的现状和世界卫生组织（WHO）到 2030 年消除疟疾的战略。
Med Sci Monit. 2023 Jan 1;29:e939357. doi: 10.12659/MSM.939357.
8
Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice.Matrix-M™ 佐剂包膜蛋白疫苗可预防致死性西尼罗病毒 1 型和 2 型感染小鼠。
Vaccine. 2014 Feb 7;32(7):800-8. doi: 10.1016/j.vaccine.2013.12.030. Epub 2013 Dec 28.
9
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial.低剂量候选疟疾疫苗 R21 联合 Matrix-M 佐剂，季节性接种在布基纳法索儿童中的效果：一项随机对照试验。
Lancet. 2021 May 15;397(10287):1809-1818. doi: 10.1016/S0140-6736(21)00943-0. Epub 2021 May 5.
10
Matrix-M™ adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine.Matrix - M™佐剂增强季节性三价病毒体流感疫苗诱导的保护作用。
Virol J. 2015 Dec 8;12:210. doi: 10.1186/s12985-015-0435-9.
本文引用的文献
1
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.疟疾疫苗候选物 R21/Matrix-M 在非洲儿童中的安全性和有效性：一项多中心、双盲、随机、3 期临床试验。
Lancet. 2024 Feb 10;403(10426):533-544. doi: 10.1016/S0140-6736(23)02511-4. Epub 2024 Feb 1.
2
Editorial: Current Status of Two Adjuvanted Malaria Vaccines and the World Health Organization (WHO) Strategy to Eradicate Malaria by 2030.社论：两种佐剂疟疾疫苗的现状和世界卫生组织（WHO）到 2030 年消除疟疾的战略。
Med Sci Monit. 2023 Jan 1;29:e939357. doi: 10.12659/MSM.939357.
3
Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial.在布基纳法索进行了 2 年的随访后，R21/Matrix-M 疫苗对儿童临床疟疾的疗效和免疫原性：一项 1/2b 期随机对照试验。
Lancet Infect Dis. 2022 Dec;22(12):1728-1736. doi: 10.1016/S1473-3099(22)00442-X. Epub 2022 Sep 7.
Zotero 插件